English 
ボストンメディカルサイエンスシリーズAラウンドでは、既存投資家である株式会社Beyond Next Venturesに加え、JIC Venture Growth Investments株式会社、株式会社グローバル・ブレイン、明治安田生命保険相互会社、東日本旅客鉄道株式会社を主幹事とする高輪地球博ファンド、三菱UFJキャピタル株式会社、株式会社ユーカリア、地域医療連携プラットフォーム株式会社を新たな投資家として迎え、9.3億円の資金調達を実施いたしました。
Founded in April 2023 by a doctor who serves as a faculty member and researcher at Harvard Medical School and Massachusetts General Hospital, the company aims to be the first in the world to clinically implement “AIM4CRC,” a laxative-free virtual endoscopy system, in Japan, with a background of strong technology and experience in AI research and development, medical image analysis, and clinical medicine. The funds raised this time will be used to further strengthen the research and development system, conduct upcoming domestic clinical trials, respond to pharmaceutical affairs in Japan and the United States, and expand the system with an eye toward market expansion.
こちらもお読みください： キーンヘルス、chatGENE Proで遺伝子検査のAI検索を開始
To date, our company has achieved accelerated growth, including being selected for the “Deep Tech Startup Support Project” by the New Energy and Industrial Technology Development Organization (NEDO), the “Priority Review for Programmed Medical Devices (Priority SaMD)” by the Ministry of Health, Labor and Welfare, and the “HealthTech Gateway “AI Medical in the US”” provided by Mayo Clinic and the Japan External Trade Organization (JETRO). All employees will work together to achieve our company’s philosophy of “eradicating colorectal cancer deaths from the world through the power of early detection and prevention” as soon as possible.
ソース PRタイムズ
日本語